Phio Pharmaceuticals develops cancer treatments that use its INTASYL RNA technology to help the immune system attack tumors. PHIO reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 26 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How PHIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
Whale Options Flow
90DNo whale options trades in PHIO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHIO is in one of them and how their past PHIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PHIO in an article yet. Here's the latest on the wider market.
About Phio Pharmaceuticals
Phio Pharmaceuticals is a clinical stage biopharmaceutical company based in King of Prussia, Pennsylvania. It is developing cancer treatments based on its INTASYL small interfering RNA technology, which is designed to silence proteins that reduce the immune system's ability to attack tumors. Its lead candidate, PH-762, is being tested in a clinical trial in patients with skin cancers, including cutaneous squamous cell carcinoma and melanoma. The therapies are designed for patients with cancer and are given by injection directly into tumors.
- Headquarters
- King Of Prussia, PA